CONSTELLATION TECHNOLOGIES LIMITED — Regulatory Filings 2011

Jul 11, 2011

==> picture [99 x 86] intentionally omitted <==

ASX Announcement

12 July 2011

Additional Link to US Peer Review Medical Journal of Study Evaluating Accuracy and Safety of ThromboView® Diagnostic

Drug and Diagnostic company Agenix Limited (ASX: AGX), recently advised that the positive results of a study to evaluate the efficacy and accuracy of its lead diagnostic, ThromboView[®] , in patients with suspected acute pulmonary embolism will be available in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).

For interested parties not able to access the AJRCCM, the full results and paper entitled Detection of Pulmonary Emboli With 99mTc-Labeled Anti-D-dimer (DI-80B3) Fab' Fragments (ThromboView) is also available online by visiting the US National Center for Biotechnology Information website or by using this link http://www.ncbi.nlm.nih.gov/pubmed/21680946

The 52 patient multi-centre Phase II study found ThromboView[®] was well tolerated by patients and enhanced the ability to accurately diagnose acute pulmonary embolism.

For more information please contact:

Nicholas Weston Andrew Geddes Agenix Limited CoActive Health Communications Tel: 1300 132 551 Tel: (02) 9555 4453

® ThromboView is a registered trademark of Agen Biomedical Limited, a wholly owned subsidiary of Agenix Limited.